-
公开(公告)号：US08008307B2
公开(公告)日：2011-08-30
申请号：US11890338
申请日：2007-08-06
Applicant: Christopher F. Claiborne , Stephen Critchley , Courtney Cullis , Steven P. Langston , Hirotake Mizutani , Edward J. Olhava , Stephane Peluso , Irache Visiers , Stepan Vyskocil , Gabriel S. Weatherhead
Inventor： Christopher F. Claiborne , Stephen Critchley , Courtney Cullis , Steven P. Langston , Hirotake Mizutani , Edward J. Olhava , Stephane Peluso , Irache Visiers , Stepan Vyskocil , Gabriel S. Weatherhead
IPC: C07D239/48 , A61K31/505
CPC classification number: C07D239/42 , A61K31/53 , C07D213/56 , C07D213/69 , C07D213/74 , C07D213/81 , C07D213/82 , C07D239/36 , C07D239/48 , C07D251/18 , C07D251/48 , C07D401/04 , C07D401/06 , C07D403/04 , C07D471/04 , C07D471/08 , C07D473/30 , C07D473/34 , C07D487/04
Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
Abstract translation: 本发明涉及抑制E1活化酶的化合物，包含该化合物的药物组合物和使用该化合物的方法。 该化合物可用于治疗疾病，特别是细胞增殖病症，包括癌症，炎症和神经变性疾病; 和与感染和恶病质相关的炎症。
-
公开(公告)号：US20080269217A1
公开(公告)日：2008-10-30
申请号：US12149440
申请日：2008-05-01
Applicant: Tricia J. Vos , Michael E. Solomon , Christopher F. Claiborne , Martin P. Maguire , Mingshi Dai , Michael Patane , Thoma H. Marsilje
Inventor： Tricia J. Vos , Michael E. Solomon , Christopher F. Claiborne , Martin P. Maguire , Mingshi Dai , Michael Patane , Thoma H. Marsilje
IPC: A61K31/5377 , A61K31/505 , C07D239/06 , A61K31/4184 , C07D235/02 , C07D233/24 , A61K31/4174 , C07D413/02
CPC classification number: C07D471/04 , A61K31/4164 , A61K31/4174 , A61K31/4184 , A61K31/505 , A61K31/5377 , C07C211/27 , C07C211/29 , C07C211/30 , C07C237/38 , C07C257/18 , C07C271/20 , C07C275/26 , C07D233/06 , C07D233/10 , C07D233/18 , C07D233/20 , C07D233/22 , C07D233/26 , C07D233/30 , C07D233/42 , C07D233/48 , C07D235/12 , C07D235/18 , C07D239/06 , C07D295/073 , C07D295/088 , C07D295/13 , C07D295/135 , C07D401/04 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/04 , C07D409/10 , C07D409/12 , C07D487/04 , C07D513/04
Abstract: Provided are MC4-R binding compounds of the formula XVII: wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
-
公开(公告)号：US20080167292A1
公开(公告)日：2008-07-10
申请号：US11985277
申请日：2007-11-14
Applicant: Christopher F. Claiborne , Todd B. Sells , Stephen G. Stroud
Inventor： Christopher F. Claiborne , Todd B. Sells , Stephen G. Stroud
IPC: A61K31/55
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
Abstract translation: 本发明涉及治疗癌症的化合物和方法。 特别地，本发明提供了极光A激酶的有效抑制剂，包含该化合物的药物组合物，以及使用该化合物治疗癌症的方法。
-
公开(公告)号：US07053089B2
公开(公告)日：2006-05-30
申请号：US10079452
申请日：2002-02-20
Applicant: Christopher F. Claiborne , John W. Butcher , David A. Claremon , Brian E. Libby , Nigel J. Liverton , Peter M. Munson , Kevin T. Nguyen , Brian Phillips , Wayne Thompson , John A. McCauley
Inventor： Christopher F. Claiborne , John W. Butcher , David A. Claremon , Brian E. Libby , Nigel J. Liverton , Peter M. Munson , Kevin T. Nguyen , Brian Phillips , Wayne Thompson , John A. McCauley
IPC: C07D401/12 , C07D403/12 , A61K31/4545
CPC classification number: C07D409/14 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D451/02 , C07D471/04 , C07D473/16 , C07D473/34 , C07D475/08
Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
-
5.发明授权公开(公告)号：US06316474B1
公开(公告)日：2001-11-13
申请号：US09696501
申请日：2000-10-25
Applicant: John A. McCauley , Cory R. Theberge , Nigel J. Liverton , David A. Claremon , Christopher F. Claiborne
Inventor： John A. McCauley , Cory R. Theberge , Nigel J. Liverton , David A. Claremon , Christopher F. Claiborne
IPC: A01N4340
CPC classification number: C07D401/06 , C07D235/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
Abstract: Benzimidazoles, substituted in the 2-position by substituted benzyl groups or heteroaryl groups are effective as NMDA NR2B antagonists and are useful for relieving pain.
Abstract translation: 通过取代的苄基或杂芳基在2-位取代的苯并咪唑作为NMDA NR2B拮抗剂是有效的，可用于缓解疼痛。
-
Patent Agency Ranking
公开(公告)号：US20120178739A1
公开(公告)日：2012-07-12
申请号：US13419663
申请日：2012-03-14
Applicant: Christopher Blackburn , Christopher F. Claiborne , Courtney A. Cullis , Natalie A. Dales , Michael Patane , Matthew Stirling , Omar Stradella , Gabriel S. Weatherhead
Inventor： Christopher Blackburn , Christopher F. Claiborne , Courtney A. Cullis , Natalie A. Dales , Michael Patane , Matthew Stirling , Omar Stradella , Gabriel S. Weatherhead
CPC classification number: C07D491/14 , C07D471/14 , C07D487/04 , C07D495/14
Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Abstract translation: 本发明提供了可用作蛋白激酶抑制剂的新化合物。 本发明还提供包含本发明化合物的药物组合物和使用该组合物治疗各种疾病的方法。
-
公开(公告)号：US20120071482A1
公开(公告)日：2012-03-22
申请号：US13216352
申请日：2011-08-24
Applicant: Christopher F. Claiborne , Stephen Critchley , Courtney Cullis , Steven P. Langston , Hirotake Mizutani , Edward J. Olhava , Stephane Peluso , Irache Visiers , Stepan Vyskocil , Gabriel S. Weatherhead
Inventor： Christopher F. Claiborne , Stephen Critchley , Courtney Cullis , Steven P. Langston , Hirotake Mizutani , Edward J. Olhava , Stephane Peluso , Irache Visiers , Stepan Vyskocil , Gabriel S. Weatherhead
IPC: A61K31/53 , A61K31/52 , A61K31/519 , A61K31/506 , A61K31/505 , A61K31/437 , A61K31/44 , C07D251/48 , C07D487/04 , A61P35/00 , C07D401/04 , C07D239/47 , C07D471/04 , C07D211/98 , C07D473/28 , C12N9/99
CPC classification number: C07D239/42 , A61K31/53 , C07D213/56 , C07D213/69 , C07D213/74 , C07D213/81 , C07D213/82 , C07D239/36 , C07D239/48 , C07D251/18 , C07D251/48 , C07D401/04 , C07D401/06 , C07D403/04 , C07D471/04 , C07D471/08 , C07D473/30 , C07D473/34 , C07D487/04
Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
Abstract translation: 本发明涉及抑制E1活化酶的化合物，包含该化合物的药物组合物和使用该化合物的方法。 该化合物可用于治疗疾病，特别是细胞增殖病症，包括癌症，炎症和神经变性疾病; 和与感染和恶病质相关的炎症。
-
公开(公告)号：US20110312942A1
公开(公告)日：2011-12-22
申请号：US13217659
申请日：2011-08-25
Applicant: Christopher F. Claiborne , Todd B. Sells , Stephen G. Stroud
Inventor： Christopher F. Claiborne , Todd B. Sells , Stephen G. Stroud
IPC: A61K31/55 , A61P35/00 , C07D487/04
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
Abstract translation: 本发明涉及治疗癌症的化合物和方法。 特别地，本发明提供了极光A激酶的有效抑制剂，包含该化合物的药物组合物，以及使用该化合物治疗癌症的方法。
-
公开(公告)号：US20110039820A1
公开(公告)日：2011-02-17
申请号：US12903370
申请日：2010-10-13
Applicant: Christopher Blackburn , Christopher F. Claiborne , Courtney A. Cullis , Natalie A. Dales , Michael Patane , Matthew Stirling , Omar Stradella , Gabriel S. Weatherhead
Inventor： Christopher Blackburn , Christopher F. Claiborne , Courtney A. Cullis , Natalie A. Dales , Michael Patane , Matthew Stirling , Omar Stradella , Gabriel S. Weatherhead
CPC classification number: C07D491/14 , C07D471/14 , C07D487/04 , C07D495/14
Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Abstract translation: 本发明提供了可用作蛋白激酶抑制剂的新化合物。 本发明还提供包含本发明化合物的药物组合物和使用该组合物治疗各种疾病的方法。
-
公开(公告)号：US07459448B2
公开(公告)日：2008-12-02
申请号：US11242413
申请日：2005-10-03
Applicant: Christopher Blackburn , Christopher F. Claiborne , Courtney A. Cullis , Natalie A. Dales , Michael Patane , Matthew Stirling , Omar Stradella , Gabriel S. Weatherhead
Inventor： Christopher Blackburn , Christopher F. Claiborne , Courtney A. Cullis , Natalie A. Dales , Michael Patane , Matthew Stirling , Omar Stradella , Gabriel S. Weatherhead
IPC: C07D487/04 , A61K31/55
CPC classification number: C07D491/14 , C07D471/14 , C07D487/04 , C07D495/14
Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Abstract translation: 本发明提供了可用作蛋白激酶抑制剂的新化合物。 本发明还提供包含本发明化合物的药物组合物和使用该组合物治疗各种疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.036 seconds)
